Alpha Cognition Inc. (NASDAQ: ACOG) reported second-quarter 2026 results that underscore a strengthening launch trajectory for its Alzheimer’s treatment ZUNVEYL, even as payer implementation remains limited. The company’s net product revenue surged 71% quarter-over-quarter to $6.0 million, driven by a 37% increase in bottles dispensed to 8,294. June emerged as the strongest demand month since launch, with 2,997 bottles dispensed, and management indicated that growth has continued into the third quarter.
The robust performance is particularly notable given that it occurred without material stocking benefits or additional formulary wins. This suggests the quarter was fueled by genuine underlying demand and improved commercial execution. Stonegate Capital Partners, which updated its coverage on the company, highlighted that the quality of the quarter was better than the access backdrop might imply, as prescriptions, repeat use, and facility adoption all advanced despite slower payer integration.
Key metrics from the quarter reveal broadening adoption and deepening utilization. The company recorded 1,347 quarterly prescribers, 1,024 repeat prescribers, and 1,908 cumulative writers. Additionally, 1,095 long-term care (LTC) facilities generated prescriptions during the quarter. With downstream pharmacy benefit manager (PBM) implementation still at approximately 16%, there is substantial room for growth as prescriber and facility productivity continues to rise and payer access expands.
“The core setup is increasingly breadth plus depth plus payer upside,” noted Stonegate. “White space remains across homes and physicians, utilization is deepening, and broader PBM implementation remains incremental to growth.” This assessment points to a multi-faceted growth strategy that leverages both expanded reach and increased per-prescriber usage.
Alpha Cognition is also balancing commercial investment with a growing evidence base. The company lowered its full-year 2026 research and development (R&D) and selling, general, and administrative (SG&A) guidance to $50 million to $54 million, while reaffirming its target of operating profitability by 2027. Several potential milestones loom, including data from the CONVERGE study expected in the third quarter of 2026, the ongoing RESOLVE trial, and the sublingual program, which is gated by comparative pharmacokinetic results.
These developments suggest that Alpha Cognition is positioning itself for greater operating leverage while continuing to invest in the ZUNVEYL launch. The company’s ability to generate strong demand growth despite limited payer coverage underscores the product’s potential and the effectiveness of its commercial strategy. As payer implementation gradually improves, the additional upside could be significant, making Alpha Cognition a company to watch in the Alzheimer’s treatment space.
